Clinically reviewed by Dr. Sarah Boss, MD
Non-stimulant does not mean risk-free. New suicidal thoughts, severe mood change, fainting or serious breathing difficulty needs prompt assessment. Do not abruptly stop guanfacine or clonidine, because blood pressure can rise dangerously.
Non-stimulant ADHD medicines provide alternatives or, in selected circumstances, additions to stimulant treatment. The group is not pharmacologically uniform. Atomoxetine and viloxazine differ from guanfacine and clonidine, and each has its own formulation, licensed age range, interactions and monitoring needs. Choosing among them should follow an assessment of ADHD-related impairment, physical health, other mental health conditions and the reasons earlier treatments did or did not help.
When might a non-stimulant be considered?
A clinician may consider a non-stimulant when stimulant treatment is not tolerated, has not provided enough benefit or is unsuitable for an individual reason. Preferences and concerns about misuse may also enter the discussion. These circumstances do not automatically identify one best medicine. It is important to distinguish an ineffective trial from a trial limited by the wrong formulation, insufficient monitoring or another untreated problem.
NICE’s UK pathway recommends atomoxetine for adults after specified stimulant options are ineffective or not tolerated. It describes atomoxetine or guanfacine for children and young people in relevant circumstances, and calls for tertiary advice before certain other uses, including guanfacine in adults. US approvals are not identical to this pathway. Always separate a guideline recommendation from the actual product license. [1]
Atomoxetine: a norepinephrine reuptake inhibitor
Atomoxetine is used for ADHD and is not a stimulant. Its benefit is assessed over time rather than by looking for an immediate stimulant-like feeling. Side effects can include digestive symptoms, appetite changes, tiredness, sleep changes and sexual or urinary difficulties. Blood pressure and pulse may increase, so non-stimulant status does not mean cardiovascular monitoring can be omitted. [2]
Important warnings include suicidal thoughts in children and adolescents and rare serious liver injury. New mood deterioration needs assessment. Yellow skin or eyes, dark urine or other possible liver symptoms require prompt clinical contact. Some antidepressants can change atomoxetine exposure, so the pharmacist should review the complete prescription list rather than assuming ADHD and depression treatments can always be combined without adjustment.
Guanfacine: an alpha-2A agonist
Guanfacine extended release is used in particular ADHD populations. Its immediate-release blood-pressure formulation should not be confused with an interchangeable ADHD prescription. Sleepiness, dizziness, low blood pressure and a slow heart rate are important considerations. Food and swallowing instructions depend on the product, and extended-release tablets should not be crushed or chewed. [3]
Stopping suddenly can cause a rise in blood pressure. Repeated missed doses or vomiting that prevents treatment should be discussed promptly, not managed by doubling the next dose. A clinician may need to specify how treatment is restarted. These precautions are particularly relevant at weekends, during travel and when a young person moves between households.
Clonidine: formulations and treatment roles differ
Clonidine has blood-pressure uses and particular extended-release ADHD formulations. Different products have different schedules and should not be substituted by matching milligrams. It may cause sleepiness, dizziness, dry mouth, low blood pressure or a slow pulse. Other sedating or blood-pressure-lowering medicines can complicate the effects. [4]
Clonidine also requires care when stopping because abrupt withdrawal can cause rebound hypertension and related symptoms. The existence of specialist clonidine use for some withdrawal symptoms does not turn an ADHD preparation into a general home-detox medicine. The indication, formulation, supervision and follow-up need to be clear for every prescription.
Viloxazine: the Qelbree extended-release product
Viloxazine extended release, marketed as Qelbree in the US, is indicated for ADHD in adults and children aged six and older. It carries a boxed warning about suicidal thoughts and behaviors and requires monitoring of mood, pulse and blood pressure. It may cause sleepiness or fatigue as well as insomnia in some people. [5]
Viloxazine inhibits CYP1A2 and has important contraindicated combinations. It also has a specific pregnancy warning that requires prompt discussion if pregnancy is recognized. Its US authorization should not be presented as evidence that it is available or routinely recommended in every country. A non-stimulant’s unfamiliar name is not a substitute for reviewing its individual risks.
How long should a treatment trial last?
Non-stimulant response is generally assessed over a planned period rather than from one day. The expected time course differs by drug, and titration is individualized. Ask when early tolerability will be checked, when meaningful improvement should be reviewed and what would make the team change course. NICE notes that non-stimulants may take longer to show benefit than stimulants. [6]
That does not mean serious adverse effects should be endured until a trial ends. New suicidal thoughts, severe agitation, fainting or marked physical deterioration needs earlier assessment. Equally, a brief good day does not prove that the full treatment plan has succeeded. Use repeated examples from everyday life and a record of unwanted effects to support the review.
What should be monitored?
Review ADHD symptoms and daily impairment alongside mood, sleep, appetite, weight, pulse and blood pressure. The direction of cardiovascular effects differs: atomoxetine and viloxazine can increase pulse or blood pressure, while alpha-2 agonists can lower them and cause rebound increases if stopped. It is misleading to describe all non-stimulants as heart-neutral alternatives.
Monitoring should fit the medicine and the person’s circumstances. Children need attention to growth and school functioning. Adults may need discussion of driving, work, caring responsibilities and sexual side effects. A baseline assessment and a clear follow-up schedule make later changes easier to interpret. Additional tests are guided by the clinical picture rather than ordered simply because a treatment is psychiatric. [1]
ADHD alongside anxiety, depression or bipolar disorder
A non-stimulant may be considered in a complex treatment plan, but its ADHD indication does not automatically establish treatment for a co-occurring disorder. Persistent panic, depression, trauma symptoms or severe insomnia should be assessed in their own right. The team should explain whether a change is intended to improve ADHD, reduce an adverse effect or address a separate condition.
A personal or family history of bipolar disorder and severe mood instability matters particularly when reviewing noradrenergic medicines. Unusually elevated mood, reduced need for sleep or major impulsive behavior is not simply a sign of better energy. New suicidal thoughts or a dramatic change in behavior requires prompt contact, and immediate danger requires emergency help. [5]
Combining medicines and checking interactions
Some ADHD formulations have evidence or authorization for use alongside a stimulant, but combination treatment is not a do-it-yourself strategy. The clinician should specify the reason, expected benefit, interactions and monitoring responsibilities. Increasing the number of medicines can make it harder to identify which drug is helping or causing a problem unless changes are planned carefully.
Bring prescriptions, supplements, nonprescription remedies and actual use to the review. Include medicines obtained from another service and products used only occasionally for sleep, pain or colds. A drug that changes another medicine’s metabolism may matter even when it does not feel sedating or stimulating. Ask for written instructions about which changes are approved and which require further advice.
Dependence, withdrawal and addiction-related care
These medicines do not all carry the same misuse profile as prescription stimulants, but lack of stimulant classification is not proof of universal safety. Guanfacine and clonidine have important physiological stopping risks. Atomoxetine and viloxazine have different discontinuation considerations. It is inappropriate to give a single withdrawal schedule for the whole group.
None should be assumed to treat alcohol, opioid or benzodiazepine withdrawal simply because it is used in ADHD care. Where substance use is present, assess the actual pattern, withdrawal risks, mood and ability to follow the plan. A non-stimulant choice may be one part of treatment, not a substitute for addiction assessment or continuing psychological and social support.
Making the plan workable
Choose a reliable dosing routine and a way to remember the actual product. Agree who requests refills and what to do if illness or supply problems interrupt treatment. For a child, ensure that caregivers understand the same instructions. For an adult, consider practical supports that do not depend on perfect memory, especially during the initial treatment period.
Bring a concise record to the next appointment: the medicine and formulation, dates of changes, benefits, unwanted effects and the most important unresolved question. The medication-review checklist can help. A treatment review should remain a shared assessment of function and well-being, not a pass-or-fail judgment of the person taking medication.
Understanding why an earlier medicine did not work
Before choosing another non-stimulant, describe the previous trial accurately. Which ingredient and formulation were used, how consistently was it taken, what improved and what caused difficulty? A treatment stopped early because of nausea is different from one taken as agreed without meaningful benefit. Neither experience should be reduced to the statement that all ADHD medication has failed.
Bring the dates of changes where possible and include any interruption in supply. Ask whether the planned observation period was completed and whether the main problem was attention, sleep, mood or an adverse effect. This is a discussion about interpreting the experience, not an invitation to repeat an intolerable trial without supervision.
A useful next-step plan names the goal, the reason for the new choice, the symptoms that need earlier contact and the follow-up date. It also states what will happen to existing prescriptions so that overlapping treatment is intentional rather than accidental. Clear instructions can reduce confusion when several services or caregivers are involved.
Frequently asked questions
Are non-stimulants always safer?
No. They have different risks rather than no risks. Mood warnings, cardiovascular effects, sedation, liver concerns, interactions and stopping precautions vary between products and people.
Can they be taken only on difficult days?
Do not assume so. Many require consistent administration and planned assessment over time. Abrupt or irregular use can be particularly problematic with guanfacine and clonidine. Follow the specific prescription.
Does a non-stimulant replace therapy or practical support?
No. Organizational strategies, environmental adjustments and psychological support may remain useful. The treatment goal is improved daily functioning, not medication use in isolation.
What happens when treatment is stopped?
The plan depends on the medicine and clinical circumstances. Discuss the reason for stopping, the method, likely symptom changes, monitoring and follow-up. Do not copy a taper intended for a different drug.


